Arcutis Biotherapeutics Q3 product revenue rises 45% on ZORYVE demand
Overview
US immuno-dermatology firm's Q3 product revenue rose 45% yr/yr, driven by ZORYVE demand growth
Q3 net income increased to $8.8 mln from $7.4 mln a year earlier
Company raised 2026 full-year net product sales guidance
Outlook
Arcutis raises 2026 full-year net product sales guidance to $535 mln–$545 mln
Company expects potential FDA approval of ZORYVE cream 0.05% for infants in Q1 2027
Arcutis to disclose Phase 2 ZORYVE foam vitiligo trial results and advancement decision by end-2026
Result Drivers
DEMAND GROWTH - Co said increased demand for ZORYVE products drove Q3 revenue growth
GTN IMPROVEMENTS - Modest improvements in gross-to-net deductions contributed to higher product revenue
MARKETING SPEND - Increased marketing, including Skin to Believe In campaign, and sales force expansion supported product growth
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | $8.80 mln | ||
Q3 Operating Expenses | $134.48 mln | ||
Q3 Operating Income | $9.44 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Arcutis Biotherapeutics, Inc. is $38.50, about 20.3% above its November 3 closing price of $32.00
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 40 three months ago
Reuters Recommended Reads
Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised
Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)